Literature DB >> 29758126

Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.

R Stagaard1,2,3, M J Flick3, B Bojko4, K Goryński4, P Z Goryńska4, C D Ley1, L H Olsen2, T Knudsen1.   

Abstract

Essentials The efficacy of systemic antifibrinolytics for hemophilic non-mucosal bleeding is undetermined. The effect of systemically inhibiting fibrinolysis in hemophilic mice and rats was explored. Neither bleeding nor the response to factor treatment was improved after inhibiting fibrinolysis. The non-mucosal bleeding phenotype in hemophilia A appears largely unaffected by fibrinolysis.
SUMMARY: Background Fibrinolysis may exacerbate bleeding in patients with hemophilia A (HA). Accordingly, antifibrinolytics have been used to help maintain hemostatic control. Although antifibrinolytic drugs have been proven to be effective in the treatment of mucosal bleeds in the oral cavity, their efficacy in non-mucosal tissues remain an open question of significant clinical interest. Objective To determine whether inhibiting fibrinolysis improves the outcome in non-mucosal hemophilic tail vein transection (TVT) bleeding models, and to determine whether a standard ex vivo clotting/fibrinolysis assay can be used as a predictive surrogate for in vivo efficacy. Methods A highly sensitive TVT model was employed in hemophilic rodents with a suppressed fibrinolytic system to examine the effect of inhibiting fibrinolysis on bleeding in non-mucosal tissue. In mice, induced and congenital hemophilia models were combined with fibrinolytic attenuation achieved either genetically or pharmacologically (tranexamic acid [TXA]). In hemophilic rats, tail bleeding was followed by whole blood rotational thromboelastometry evaluation of the same animals to gauge the predictive value of such assays. Results The beneficial effect of systemic TXA therapy observed ex vivo could not be confirmed in vivo in hemophilic rats. Furthermore, neither intravenously administered TXA nor congenital knockout of the fibrinolytic genes encoding plasminogen or tissue-type plasminogen activator markedly improved the TVT bleeding phenotype or response to factor therapy in hemophilic mice. Conclusions The findings here suggest that inhibition of fibrinolysis is not effective in limiting the TVT bleeding phenotype of HA rodents in non-mucosal tissues.
© 2018 Novo Nordisk A/S, Journal of Thrombosis and Haemostasis. © 2018 International Society on Thrombosis.

Entities:  

Keywords:  blood coagulation factors; fibrinolysis; hemophilia A; tail; tranexamic acid

Mesh:

Substances:

Year:  2018        PMID: 29758126      PMCID: PMC8040545          DOI: 10.1111/jth.14148

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  53 in total

1.  A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B.

Authors:  M Stubbs; J Lloyd
Journal:  Aust Dent J       Date:  2001-03       Impact factor: 2.291

2.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.

Authors:  J H Foley; M E Nesheim; G E Rivard; K E Brummel-Ziedins
Journal:  Haemophilia       Date:  2011-09-20       Impact factor: 4.287

3.  Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules.

Authors:  P B Johansen; M Tranholm; J Haaning; T Knudsen
Journal:  Haemophilia       Date:  2016-03-03       Impact factor: 4.287

4.  Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model.

Authors:  Ellen Vercauteren; Jan Emmerechts; Miet Peeters; Marc F Hoylaerts; Paul J Declerck; Ann Gils
Journal:  Blood       Date:  2011-02-22       Impact factor: 22.113

5.  Tranexamic acid in the control of spontaneous bleeding in severe haemophilia.

Authors:  S G Rainsford; A J Jouhar; A Hall
Journal:  Thromb Diath Haemorrh       Date:  1973-11

6.  Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.

Authors:  T Elm; D M Karpf; K Øvlisen; H Pelzer; M Ezban; M Kjalke; M Tranholm
Journal:  Haemophilia       Date:  2011-07-19       Impact factor: 4.287

7.  Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.

Authors:  L Bi; A M Lawler; S E Antonarakis; K A High; J D Gearhart; H H Kazazian
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

8.  An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.

Authors:  Catherine J Rea; Jonathan H Foley; David H Bevan; Benny Sørensen
Journal:  Ann Hematol       Date:  2013-11-06       Impact factor: 3.673

9.  Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice.

Authors:  V A Ploplis; P Carmeliet; S Vazirzadeh; I Van Vlaenderen; L Moons; E F Plow; D Collen
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

Review 10.  Continuous infusion.

Authors:  S Schulman
Journal:  Haemophilia       Date:  2003-07       Impact factor: 4.287

View more
  4 in total

1.  Hypofibrinogenemia with preserved hemostasis and protection from thrombosis in mice with an Fga truncation mutation.

Authors:  Woosuk S Hur; David S Paul; Emma G Bouck; Oscar A Negrón; Jean-Marie Mwiza; Lauren G Poole; Holly M Cline-Fedewa; Emily G Clark; Lih Jiin Juang; Jerry Leung; Christian J Kastrup; Tatiana P Ugarova; Alisa S Wolberg; James P Luyendyk; Wolfgang Bergmeier; Matthew J Flick
Journal:  Blood       Date:  2022-03-03       Impact factor: 22.113

2.  A reactive center loop-based prediction platform to enhance the design of therapeutic SERPINs.

Authors:  Wariya Sanrattana; Thibaud Sefiane; Simone Smits; Nadine D van Kleef; Marcel H Fens; Peter J Lenting; Coen Maas; Steven de Maat
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-09       Impact factor: 11.205

3.  Bleeding is increased in amyloid precursor protein knockout mouse.

Authors:  Nima Mazinani; Amy W Strilchuk; James R Baylis; Woosuk S Hur; Wilfred A Jefferies; Christian J Kastrup
Journal:  Res Pract Thromb Haemost       Date:  2020-06-14

4.  Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

Authors:  Rikke Stagaard; Carsten Dan Ley; Kasper Almholt; Lisbeth Høier Olsen; Tom Knudsen; Matthew J Flick
Journal:  Blood Adv       Date:  2018-11-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.